Key Highlights

• British American Tobacco p.l.c. (LSE:BATS) published a 2026 H1 pre-close trading update on 2 June 2026, stating it is "firmly on track to deliver FY guidance."

• The company now expects mid-teens New Category revenue growth for both H1 and FY 2026, led by Modern Oral and Vapour.

• BAT cited strong U.S. revenue and profit growth across combustibles, Modern Oral and Vapour, with performance skewed to H1.

• The group reaffirmed its mid-term algorithm of 3-5% revenue, 4-6% APFO and 5-8% adjusted diluted EPS growth, with 2026 expected at the lower end of these ranges.

• BAT confirmed plans for a progressive dividend and sustainable share buy-backs of £1.3bn in 2026, with leverage targeted at 2.0-2.5x by year-end.

Introduction

The 2 June 2026 RNS announcement from British American Tobacco p.l.c. (LSE:BATS) is a genuine trading update rather than a routine administrative disclosure, and it offers investors a richer read on how the FTSE 100 tobacco and nicotine group is performing ahead of its first-half results. Headlined with the message that the company is "firmly on track to deliver FY guidance, driven by continued U.S. delivery and New Category momentum," the update touches on revenue trends, regional performance, capital allocation and the group's medium-term financial framework. For anyone following LSE stocks and the steady cadence of company announcements that move the UK stock market, a pre-close trading update from a company of BAT's size is a notable event. It provides a checkpoint between formal reporting periods and helps shape broker sentiment and the share price outlook. This article translates the update into plain English, sets it in context, and flags the risks and uncertainties. Throughout, the figures cited are the company's own guidance, not certainties, and readers should consult the full RNS announcement for the complete picture.

British American Tobacco (LSE:BATS): Company Background

British American Tobacco p.l.c. is a FTSE 100 multinational tobacco and nicotine company and one of the largest names of its kind listed on the London Stock Exchange. Its portfolio spans traditional combustible cigarettes – with heritage brands including Dunhill and Lucky Strike – alongside a growing range of so-called New Category products designed to offer alternatives to smoking. These include Velo in Modern Oral nicotine pouches, Vuse in Vapour, and glo in heated tobacco. The company has spent recent years repositioning itself around these New Category lines as part of a broader industry shift towards reduced-risk products, while continuing to generate substantial cash from its combustible business. As a major dividend payer and a heavyweight constituent of the FTSE 100, BAT is closely watched among income-oriented holders of UK shares. The background here is widely understood; the specifics that matter for this update are set out in the RNS itself, and that is where investors should look for the authoritative detail.

What the RNS Announcement Says: Plain-English Summary

In plain terms, BAT used its pre-close trading update to reassure the market that full-year delivery "remains firmly on track." The standout operational message concerns New Category products: the company now expects mid-teens New Category revenue growth for both the first half and the full year of 2026, led by Modern Oral and Vapour. It singled out Velo for continued strong revenue and category-contribution growth globally and said it had extended its global category volume share leadership in Modern Oral. On a regional basis, BAT highlighted strong U.S. revenue and profit growth across combustibles, Modern Oral and Vapour, noting that this performance is skewed to the first half because the group is lapping a stronger second-half comparator. It described resilient delivery in its AME (Americas and Europe) region, which it expects to accelerate in the second half, and a stabilising APMEA (Asia-Pacific, Middle East and Africa) region through the year, with sequential improvement in H1 versus the second half of 2025. Group profit delivery is expected to be weighted towards the second half, helped by the increasing realisation of its Fit2Win cost savings.

The Most Important Details

Several details stand out as particularly important. First, the reaffirmation of the mid-term financial algorithm: BAT expressed confidence in sustainably delivering 3-5% revenue growth, 4-6% adjusted profit from operations (APFO) growth and 5-8% adjusted diluted EPS growth, while noting that 2026 is expected to land at the lower end of these ranges. That framing is meaningful because it both confirms the medium-term ambition and signals a measured near-term expectation. Second, capital allocation: the company pointed to strong cash generation, said it is on track to reduce leverage to within 2.0-2.5x by year-end, and confirmed a progressive dividend alongside sustainable share buy-backs of £1.3bn in 2026. Third, the technical guidance underpinning the full year. BAT now expects global cigarette industry volume to fall by around 2.5% (previously around 2%), a transactional FX headwind of around 1%, a translational FX headwind of 2-3% on adjusted diluted EPS, net finance costs of around £1.75bn (previously £1.8bn), operating cash flow conversion in excess of 95%, and gross capital expenditure of around £750m. These figures collectively shape how the group expects the year to unfold.

Why Investors May Be Watching British American Tobacco (LSE:BATS)

Investors may be watching BAT for a combination of income and transformation reasons. As a long-standing dividend payer, the company's commitment to a progressive dividend and a defined buy-back programme is central to the thesis many holders have for the shares. The confirmation of £1.3bn of sustainable share buy-backs in 2026, alongside a target to bring leverage within 2.0-2.5x by year-end, speaks directly to that capital-return story. At the same time, the transition towards New Category products is a structural narrative that many market participants follow closely, and the guidance for mid-teens New Category revenue growth provides a fresh data point on that journey. The CEO, Tadeu Marroco, was quoted reaffirming that full-year delivery "remains firmly on track," welcoming the FDA's recent prioritisation guidance, and noting that the company is monitoring developments in the Middle East with no significant impact on the group at this time. For followers of FTSE stocks, these qualitative comments add colour to the numbers. None of this, however, should be read as a prediction of where the shares will trade, and the full detail belongs in the RNS.

Market Context

The market context for this update is a UK stock market in which large, cash-generative consumer staples like BAT occupy a particular niche. Trading updates from such companies are scrutinised not only for their headline messages but for the nuance in their regional and category commentary. The fact that BAT's U.S. performance is skewed to the first half because it is lapping a stronger second-half comparator is exactly the kind of detail that informs how analysts interpret the shape of the year. Similarly, the description of group profit as H2-weighted, supported by Fit2Win savings, sets expectations for how the company's earnings may phase across 2026. For investors comparing LSE stocks, the combination of a reaffirmed guidance message, a defined buy-back and a progressive dividend places BAT within a familiar category of income-and-cash-return names. Yet market context cuts both ways: sentiment towards the tobacco sector can be influenced by regulation, litigation risk and shifting consumer attitudes, all of which sit outside the scope of any single announcement. The authoritative source remains the full RNS.

Industry Context

The tobacco and nicotine industry is in the midst of a long transition. Combustible cigarette volumes have been in structural decline across many markets, a trend reflected in BAT's revised guidance for global cigarette industry volume to fall by around 2.5% in 2026, up from a previous estimate of around 2%. Against that backdrop, the major players have invested heavily in New Category products – Modern Oral pouches, Vapour and heated tobacco – as they seek to build new revenue streams that can offset declining cigarette volumes over time. BAT's emphasis on mid-teens New Category revenue growth, its claim of extended global category volume share leadership in Modern Oral, and the strong performance of Velo all speak to that industry-wide pivot. Regulation is a defining feature of the sector, which is why the CEO's reference to welcoming the FDA's recent prioritisation guidance is notable; regulatory clarity can materially affect how these products are brought to market. The industry also faces geopolitical and macroeconomic exposures, illustrated by BAT's note that it is monitoring Middle East developments. These are structural industry dynamics, and the specifics for BAT are best read in its own disclosures.

Potential Opportunities

The potential opportunities highlighted by this update centre on the interplay between cash generation, capital returns and the New Category transition. If the company delivers the mid-teens New Category revenue growth it now expects, that would represent continued progress in building revenue streams beyond combustibles. The realisation of Fit2Win savings, which BAT says will help support H2-weighted group profit, points to a cost-efficiency lever that could support margins. On capital allocation, the combination of a progressive dividend, £1.3bn of sustainable share buy-backs in 2026, strong cash generation and a target to reduce leverage to within 2.0-2.5x by year-end together describe a framework that prioritises both returns and balance-sheet discipline. Stabilisation in APMEA through the year and an expected acceleration in AME in the second half could, if realised, support the group's overall trajectory. It bears repeating that all of these are company expectations rather than guaranteed outcomes, and that the share price outlook depends on far more than the contents of one trading update. Investors should weigh these possibilities against the risks and read the full RNS.

Key Risks and Uncertainties

A balanced reading requires careful attention to the risks. First, all the figures in the update are guidance, and BAT itself flags that 2026 is expected to be at the lower end of its mid-term ranges of 3-5% revenue, 4-6% APFO and 5-8% adjusted diluted EPS growth. Second, the structural decline in cigarette volumes – now guided at around 2.5% globally for 2026, steeper than the prior around 2% – is a persistent headwind for the combustible business that the New Category lines must offset over time. Third, currency movements present a clear risk: the company points to a transactional FX headwind of around 1% and a translational FX headwind of 2-3% on adjusted diluted EPS. Fourth, regulation and geopolitics loom large; while BAT says it is monitoring Middle East developments with no significant impact at this time, such situations can change. Fifth, the H2-weighting of group profit means the full-year outcome depends on second-half delivery, which carries execution risk. None of these points implies a particular direction for the share price, which could move either way. The prudent approach is to read the full RNS announcement and conduct independent research.

What Could Move the Share Price Next

Several catalysts could influence the British American Tobacco (LSE:BATS) share price in the coming months, though it would be unwise to single out any one as decisive. The most obvious is the company's first-half results, against which the market will test the "firmly on track" message contained in this pre-close update. Delivery on New Category growth, the pace of Fit2Win savings, and the shape of the H2-weighted profit profile will all attract scrutiny. Capital-return news – the progression of the £1.3bn buy-back, the dividend and the leverage trajectory towards 2.0-2.5x – could shape broker sentiment. External factors such as FX movements, regulatory developments (including how the FDA's prioritisation guidance plays out), and geopolitical events in regions like the Middle East may also move the dial. Broader stock market news and sentiment towards the tobacco sector will provide the backdrop. Investors should treat the share price outlook as inherently uncertain and avoid drawing firm conclusions from a single company announcement. Monitoring official RNS disclosures is the most reliable way to stay informed.

Long-Term Outlook

Over the long term, British American Tobacco's prospects hinge on the success of its transformation towards New Category products, its ability to manage the structural decline in combustible volumes, and its discipline in capital allocation. The reaffirmation of a mid-term algorithm targeting 3-5% revenue, 4-6% APFO and 5-8% adjusted diluted EPS growth provides a framework for how management thinks about the medium term, while the note that 2026 will sit at the lower end of those ranges tempers near-term expectations. The combination of a progressive dividend, sustainable buy-backs and a leverage target speaks to a long-running emphasis on cash returns and balance-sheet health. Yet a genuine long-term view requires far more than a single trading update: regulatory trends, litigation risk, consumer behaviour, competitive dynamics and the economics of New Category products will all matter over a multi-year horizon. This article offers no prediction about the shares. Readers building a long-term thesis should study BAT's full financial disclosures and consider seeking advice from a qualified financial adviser.

Conclusion

British American Tobacco p.l.c. (LSE:BATS) used its 2 June 2026 pre-close trading update to reassure investors that it remains "firmly on track" for full-year 2026, pointing to strong U.S. delivery and mid-teens New Category revenue growth led by Modern Oral and Vapour. The update reaffirmed the group's mid-term algorithm – while flagging 2026 at the lower end – and confirmed a progressive dividend, £1.3bn of share buy-backs and a leverage target of 2.0-2.5x by year-end. Technical guidance on cigarette volumes, FX, finance costs, cash conversion and capex rounds out the picture. For followers of FTSE stocks and the wider UK stock market, it is a substantive company announcement that warrants attention. But the figures are guidance, not guarantees, and this article makes no forecast. The sensible next step is to read the full RNS announcement and assess it within the context of one's own research.